140 related articles for article (PubMed ID: 7541496)
21. Non-Clinical Efficacy and Safety Studies on G1XCGD, a Lentiviral Vector for Ex Vivo Gene Therapy of X-Linked Chronic Granulomatous Disease.
Brendel C; Rothe M; Santilli G; Charrier S; Stein S; Kunkel H; Abriss D; Müller-Kuller U; Gaspar B; Modlich U; Galy A; Schambach A; Thrasher AJ; Grez M
Hum Gene Ther Clin Dev; 2018 Jun; 29(2):69-79. PubMed ID: 29664709
[TBL] [Abstract][Full Text] [Related]
22. Generation of recombinant adeno-associated virus (rAAV) from an adenoviral vector and functional reconstitution of the NADPH-oxidase.
Thrasher AJ; de Alwis M; Casimir CM; Kinnon C; Page K; Lebkowski J; Segal AW; Levinsky RJ
Gene Ther; 1995 Sep; 2(7):481-5. PubMed ID: 7584126
[TBL] [Abstract][Full Text] [Related]
23. Lentiviral gene therapy for X-linked chronic granulomatous disease.
Kohn DB; Booth C; Kang EM; Pai SY; Shaw KL; Santilli G; Armant M; Buckland KF; Choi U; De Ravin SS; Dorsey MJ; Kuo CY; Leon-Rico D; Rivat C; Izotova N; Gilmour K; Snell K; Dip JX; Darwish J; Morris EC; Terrazas D; Wang LD; Bauser CA; Paprotka T; Kuhns DB; Gregg J; Raymond HE; Everett JK; Honnet G; Biasco L; Newburger PE; Bushman FD; Grez M; Gaspar HB; Williams DA; Malech HL; Galy A; Thrasher AJ;
Nat Med; 2020 Feb; 26(2):200-206. PubMed ID: 31988463
[TBL] [Abstract][Full Text] [Related]
24. Gene therapy for chronic granulomatous disease.
Barese CN; Goebel WS; Dinauer MC
Expert Opin Biol Ther; 2004 Sep; 4(9):1423-34. PubMed ID: 15335310
[TBL] [Abstract][Full Text] [Related]
25. Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease.
Mardiney M; Jackson SH; Spratt SK; Li F; Holland SM; Malech HL
Blood; 1997 Apr; 89(7):2268-75. PubMed ID: 9116268
[TBL] [Abstract][Full Text] [Related]
26. Drug-selected complete restoration of superoxide generation in Epstein-Barr virus-transformed B cells from p47phox-deficient chronic granulomatous disease patients by using a bicistronic retrovirus vector encoding a human multi-drug resistance gene (MDR1) and the p47phox gene.
Iwata M; Nunoi H; Matsuda I; Kanegasaki S; Tsuruo T; Sugimoto Y
Hum Genet; 1998 Oct; 103(4):419-23. PubMed ID: 9856484
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and carrier detection of chronic granulomatous disease in five families by flow cytometry.
Crockard AD; Thompson JM; Boyd NA; Haughton DJ; McCluskey DR; Turner CP
Int Arch Allergy Immunol; 1997 Oct; 114(2):144-52. PubMed ID: 9338608
[TBL] [Abstract][Full Text] [Related]
28. Chronic granulomatous disease. Molecular genetics.
Dinauer MC; Orkin SH
Hematol Oncol Clin North Am; 1988 Jun; 2(2):225-40. PubMed ID: 3292508
[TBL] [Abstract][Full Text] [Related]
29. NADPH-binding component of the superoxide-generating oxidase in unstimulated neutrophils and the neutrophils from the patients with chronic granulomatous disease.
Umei T; Takeshige K; Minakami S
Biochem J; 1987 Apr; 243(2):467-72. PubMed ID: 3632631
[TBL] [Abstract][Full Text] [Related]
30. [Chronic granulomatous disease diagnosis: Patients and carriers].
Ramírez-Vargas NG; Berrón-Ruiz LR; Berrón-Pérez R; Blancas-Galicia L
Rev Alerg Mex; 2011; 58(2):120-5. PubMed ID: 21967972
[TBL] [Abstract][Full Text] [Related]
31. Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease.
Ezekowitz RA; Orkin SH; Newburger PE
J Clin Invest; 1987 Oct; 80(4):1009-16. PubMed ID: 2821069
[TBL] [Abstract][Full Text] [Related]
32. Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial.
Kang HJ; Bartholomae CC; Paruzynski A; Arens A; Kim S; Yu SS; Hong Y; Joo CW; Yoon NK; Rhim JW; Kim JG; Von Kalle C; Schmidt M; Kim S; Ahn HS
Mol Ther; 2011 Nov; 19(11):2092-101. PubMed ID: 21878903
[TBL] [Abstract][Full Text] [Related]
33. Functional Restoration of gp91phox-Oxidase Activity by BAC Transgenesis and Gene Targeting in X-linked Chronic Granulomatous Disease iPSCs.
Laugsch M; Rostovskaya M; Velychko S; Richter C; Zimmer A; Klink B; Schröck E; Haase M; Neumann K; Thieme S; Roesler J; Brenner S; Anastassiadis K
Mol Ther; 2016 Apr; 24(4):812-22. PubMed ID: 26316390
[TBL] [Abstract][Full Text] [Related]
34. Lentiviral Vector Gene Therapy Protects XCGD Mice From Acute Staphylococcus aureus Pneumonia and Inflammatory Response.
Farinelli G; Jofra Hernandez R; Rossi A; Ranucci S; Sanvito F; Migliavacca M; Brombin C; Pramov A; Di Serio C; Bovolenta C; Gentner B; Bragonzi A; Aiuti A
Mol Ther; 2016 Oct; 24(10):1873-1880. PubMed ID: 27456061
[TBL] [Abstract][Full Text] [Related]
35. Lentivirus-mediated gene transfer of gp91phox corrects chronic granulomatous disease (CGD) phenotype in human X-CGD cells.
Saulnier SO; Steinhoff D; Dinauer MC; Zufferey R; Trono D; Seger RA; Hossle JP
J Gene Med; 2000; 2(5):317-25. PubMed ID: 11045425
[TBL] [Abstract][Full Text] [Related]
36. Gene therapy for chronic granulomatous disease.
Kang EM; Malech HL
Methods Enzymol; 2012; 507():125-54. PubMed ID: 22365772
[TBL] [Abstract][Full Text] [Related]
37. Chronic granulomatous disease.
Dinauer MC; Orkin SH
Annu Rev Med; 1992; 43():117-24. PubMed ID: 1316094
[TBL] [Abstract][Full Text] [Related]
38. Delineation of the phagocyte NADPH oxidase through studies of chronic granulomatous diseases of childhood.
Gallin JI
Int J Tissue React; 1993; 15(3):99-103. PubMed ID: 8188451
[TBL] [Abstract][Full Text] [Related]
39. Recent Advances in Gene Therapy and Modeling of Chronic Granulomatous Disease.
Jafarian A; Shokri G; Shokrollahi Barough M; Moin M; Pourpak Z; Soleimani M
Iran J Allergy Asthma Immunol; 2019 Apr; 18(2):131-142. PubMed ID: 31066249
[TBL] [Abstract][Full Text] [Related]
40. Signed outside: a surface marker system for transgenic cytoplasmic proteins.
Wohlgensinger V; Seger R; Ryan MD; Reichenbach J; Siler U
Gene Ther; 2010 Oct; 17(10):1193-9. PubMed ID: 20445581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
